Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
46 results about "Phenobarbital" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
This medication is used alone or with other medications to control seizures.
Use of the phytocannabinoid cannabidivarin (CBDV) in the treatment of epilepsy
ActiveUS9125859B2Growth inhibitionReduces high-frequency neuronal firingBiocideNervous disorderValproic AcidPhenobarbital
Owner:GW PHARMA LTD
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
InactiveUS20060074451A1Raise the possibilityIncrease heart rateSpinal electrodesHeart stimulatorsDiseaseAntiarrhythmic effect
Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.
Owner:CEDARS SINAI MEDICAL CENT
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
Owner:CEDARS SINAI MEDICAL CENT
Phenobarbital derivatives useful in immunoassay
Phenobarbital derivatives synthesized out of the alkyl chain at the 5-position, particularly with hydrophilic properties, and carrying an active ester at the end, allow formation of aminodextran conjugates that give curves in the desired range of the assay in the ONLINE TDM microparticle assay format when matched against the Roche FPIA antibody specific for phenobarbital (''an antibody specific for phenobarbital'').
Owner:F HOFFMANN LA ROCHE & CO AG
Method for detecting blood concentration of multiple antiepileptic drugs simultaneously
InactiveCN1971270ASuitable for routine testingDo not interfere with determinationTesting dairy productsTesting medicinal preparationsEpoxyPretreatment method
The invention belongs to field of medical examination and relates to assay determination method of internal medicine, specially a detecting method of six antiepileptics medicines of primidone, phenylethylmalonylurea, diphenylhydantoin, carbamazepine, Larmortriazine, okazepine and the active product monohydroxy okazepine of okazepine and the active product epoxy carbamazepine of carbamazepine in human plasma. The sample to be measured is eluted equicontinuously in condition of acidic mobile phase via the pretreatment of protein precipitation, and separated by chromatographic column, and detected by ultraviolet detector. The quantity of sample in the invention is small; the pretreatment method is simple, fast and sensitive, free of expensive apparatus and agents, applicability is wide, cost is low, it fits for the detection of normal blood concentration in clinic.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Phenobarbital homogeneous-phase enzyme immunoassay reagent kit and preparation method thereof
ActiveCN102323414AImprove accuracyHigh precisionImmunoglobulinsMaterial analysisDrug interactionEnzyme immunoassays
Owner:西安金域医学检验所有限公司
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
InactiveUS20060004414A1Raise the possibilityIncrease heart rateCatheterHeart stimulatorsDiseaseAntiarrhythmic effect
Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.
Owner:CEDARS SINAI MEDICAL CENT
Method for detecting residual tranquilizer medicines in meat product
The invention discloses a method for detecting residual tranquilizer medicines in a meat product. The method comprises the following steps: extracting and purifying by adopting a C18 solid phase extracting column, and then detecting by adopting a gas chromatography-mass spectrometer (GC-MS), so as to rapidly and exactly detect out the variety and the content of the residual tranquilizer medicines, including seven tranquilizer medicines, namely, diazepam, oxazepam, estazolam, alprazolam, triazolam, phenobarbital and promethazine, in the meat product. The method is suitable for detecting multiple tranquilizer medicine residues in complex substrate meat products such as sausage; the method has the advantages of being low in detection limit, accurate, fast, easy and convenient in operation and economic in detection cost, and can be developed and applied in detection mechanisms.
Owner:广东省中山市质量计量监督检测所
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.
Owner:CEDARS SINAI MEDICAL CENT
Phenobarbital derivative and preparation method and application thereof
ActiveCN102757391AStrong specificityImprove accuracySerum albuminImmunoglobulinsPharmaceutical drugPhenobarbital
The invention discloses a phenobarbital derivative, a preparation method thereof, a phenobarbital immunogen directly obtained from the derivative, a phenobarbital specific antibody indirectly obtained from the derivative, and a detection reagent containing the specific antibody. The preparation method has the beneficial effects: a novel phenobarbital derivative is used, so that various main functional radicals of phenobarbital are retained, and higher performance of identifying and distinguishing nonspecific medicaments is realized; the phenobarbital immunogen and phenobarbital antibody with high specificity are prepared from the novel phenobarbital derivative, and do not undergo any cross reaction with the conventional 45 kinds of medicaments; and the phenobarbital detection reagent can be used for detecting a plurality samples simultaneously on a full-automatic biochemistry analyzer, so that high-flux rapid determination of phenobarbital is realized, high accuracy and high specificity are achieved, the accuracy and detection efficiency are greatly increased than before, and full automation of a detection process is realized simultaneously.
Owner:苏州博源医疗科技有限公司
Method for measuring density of anti-epileptic in blood
InactiveCN101093214ASimple and fast operationEasy to operateComponent separationColor/spectral properties measurementsUltraviolet detectorsAntiepileptic drug
A method for determining blood-medicine concentration of antiepileptic medicine includes pre-treating sample to be determined and separating pretreated sample by acidic mobile phase in chromatographic column then utilizing ultraviolet detector to simultaneously detect quantitative concentration of phenobarbital, lamotrigine, oxcarbazepin and adipomono- oxcarbazepin as antiepileptic medicine.
Owner:AFFILIATED HUSN HOSPITAL OF FUDAN UNIV
Method and system for the prediction of cardiac arrhythmias
InactiveUS20060004413A1Raise the possibilityHeart stimulatorsSensorsAntiarrhythmic effectValproic Acid
Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the left stellate ganglion, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering anti-arrhythmic therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of anti-arrhythmic therapy include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenyloin, carbamazepine, valproate, and phenobarbitone.
Owner:CEDARS SINAI MEDICAL CENT
Method and system for the prediction of cardiac arrhythmias, myocardial ischemia, and other diseased condition of the heart associated with elevated sympathetic neural discharges
Methods and systems are provided for determining an increased likelihood of the occurrence of a cardiac arrhythmia, myocardial ischemia, congestive heart failure and other diseased conditions of the heart associated with elevated sympathetic neural discharges in a patient. The methods and systems comprise monitoring the sympathetic neural discharges of a patient from the stellate ganglia, the thoracic ganglia, or both, and detecting increases in the sympathetic neural discharges. The methods and systems may further comprise delivering therapy to the patient in response to a detected increase in the sympathetic neural discharge, such as delivering one or more pharmacological agents; stimulating myocardial hyperinnervation in the sinus node and right ventricle of the heart of the patient; and applying cardiac pacing, cardioversion or defibrillation shocks. Pharmacologic agents which may be used in connection with the delivery of include those which are known to exert anti-arrhythmic effect and anti-convulsant agents, such as phenytoin, carbamazepine, valproate, and phenobarbitone. Other pharmacologic agents may be used to treat impending myocardial ischemia and other diseased conditions of the heart associated with elevated sympathetic neural discharges.
Owner:CEDARS SINAI MEDICAL CENT
Phenobarbital fast detecting test paper bar
The present invention discloses a phenobarbital quick detection test paper strip. It contains bottom layer as supporting layer, intermediate layer as adsorption layer and protective layer fixed on the adsorption layer, Said adsorption layer successively includes test end adsorption fibre layer, adsorption gold-labelled amtibody fibre layer, cellulose membrane layer and water-absorbing material layer of handle end. Besides, said invention also provides the concrete structure on the cellulose membrane layer, said structure include linear detection blotting and linear reference blotting.
Owner:河南省动物免疫学重点实验室
Compound immunoaffinity column for purifying phenobarbital and ractopamine as well as preparation method and application of compound immunoaffinity column
InactiveCN104784973AQuick checkAccurate detectionOther chemical processesPreparing sample for investigationImmunosorbentsPhenobarbital
The invention discloses a compound immunoaffinity column for purifying phenobarbital and ractopamine as well as a preparation method and an application of the compound immunoaffinity column. 4% columnar agarose gel is adopted as a solid-phase carrier, the agarose gel is coupled with a phenobarbital antibody prepared with the method and a ractopamine antibody purchased in the market to form an immunoadsorbent, and the immunoadsorbent is put into a column to prepare the immunoaffinity column. When a sample containing phenobarbital and ractopamine passes through the immunoaffinity column, the immunoadsorbent specifically adsorbs phenobarbital and ractopamine, other impurities flow out of the immunoaffinity column, and then methanol is used to wash off phenobarbital and ractopamine from the column, so that the sample is well purified. The immunoaffinity column purification and liquid chromatography methods are created for detecting phenobarbital and ractopamine, so that the detection is quick, accurate and safe.
Owner:INSPECTION & QUARANTINE TECH CENT OF CHONGQING ENTRY EXIT INSPECTION & QUARANTINE BUREAU +3
Florfenicol hybridoma cell strain, monoclonal antibody, complex immunosorbent, immunoaffinity column, kit and applications of monoclonal antibody, complex immunosorbent, immunoaffinity column and kit
InactiveCN106754733AEasy to purifyStrong specificityOther chemical processesOrganic compound preparationImmunosorbentsMedicine
The invention discloses a hybridoma cell strain with the accession number being CGMCC NO.9206, a florfenicol-resisting monoclonal antibody secreted by the cell strain, and applications of monoclonal antibody. The invention further provides an immunosorbent, the immunosorbent comprises a solid phase carrier and antibodies coupled to the solid phase carrier, and the antibodies comprise the monoclonal antibody and a phenobarbital-resisting antibody. The invention further provides an immunoaffinity column for loading the immunosorbent. The invention further provides a kit containing the immunosorbent or the immunoaffinity column, and applications of the immunosorbent, the immunoaffinity column or the kit in purifying and / or detecting florfenicol and phenobarbital, and also provides a purifying method and a detecting method. With the adoption of the product and the method provided by the invention, the simultaneous purifying and / or detecting for florfenicol and phenobarbital are / is realized.
Owner:CHINESE ACAD OF INSPECTION & QUARANTINE +3
Medicine for treating toothache
A medicine for treating toothache, dental marrow inflammation and periodontitis is prepared from VB1, VC, aminopyrine, phenacetin, coffeine, austrominal, prednisone acetate, and safflower.
Owner:王明贤
Phenobarbital oral cavity instant membrane and preparation method thereof
The invention belongs to the field of pharmaceutic preparations, particularly relates to a phenobarbital oral cavity instant membrane and a preparation method thereof. The instant membrane comprises the following components in parts by weight: 5-10 parts of phenobarbital, 10-50 parts of a film-forming material, 1-10 parts of a plasticizer and 1-6 parts of a saliva irritant. According to the phenobarbital oral cavity instant membrane and the preparation method thereof, provided by the invention, due to the form of the membrane, drug administration can be carried out without water, the membrane can melt quickly in the oral cavity, that drugs are hidden in or spat out from the oral cavity of a patient is avoided, and the medication compliance of the patient is improved; besides, the main drugs of the instant membrane prepared by adopting the preparation method provided by the invention can be uniformly dispersed in a film-forming material, the finished product is good in appearance, the main drugs can quickly dissolve and is good in stability, the dosage of the product is accurate, dust flying in the production process is hardly caused, and the problem of labor protection and environmental pollution is solved.
Owner:HEFEI HUAFANG PHARMA SCI & TECH
Compound tetracaine composition as well as preparation method and application thereof
ActiveCN102579457APromote wound healingPromote healingHydroxy compound active ingredientsAntipyreticPhenobarbitalSuppository
The invention relates to a compound tetracaine composition as well as a preparation method and application thereof. The composition comprises the following raw medicines: tetracaine, ephedrine, phenobarbital, diphenhydramine, hydrocortisone and borneol. The compound tetracaine composition has the effects of removing necrotic tissue and promoting granulation, clearing heat and relieving pain, diminishing inflammation and resisting infection and promoting wound healing and has obvious curative effects of treating acute-stage anal fissure and acute attack of chronic anal fissure. When the compound tetracaine composition is matched with an anus suppository to perform non-surgical treatment of piles, the curative effects of the compound tetracaine composition on relieving bleeding, pain and abjection symptoms of piles are obvious. As a whole, the compound tetracaine composition has the advantages of obvious curative effect and the like, is quick to act, is convenient to use and is safe; and when the compound tetracaine composition is used, a patient does not feel pain; and effective rate reaches 100%.
Owner:BEIJING RECTUM HOSPITAL
Phenobarbitone chewable tablets for dog or cat
InactiveCN101190225ABreak through the shortcomings of poor palatabilityFully absorbedOrganic active ingredientsNervous disorderOral glucoseDisease
The invention discloses a phenobarbital chewable tablet used for dogs and cats. The invention overcomes the poor palatability defect of the existing tablet to promote the thorough chewing absorption by dogs and cats, so as to effectively guarantee the medicine-supply dose, to enhance the cure rate of diseases of dogs and cats and to reduce the medicine waste. The tablet of the invention comprises the following components represented by weight-percentage: 1 to 5 percent of aspartame; 20 to 30 percent of a mixture of oral dextrose and degreased milk powder; the ratio of 1:1 to 1:4 between the oral dextrose and degreased milk powder in the mixture; 40 to 60 percent of excipient; 0.5 to 1 percent of glidant and 10 to 30 percent of phenobarbital.
Owner:TIANJIN RINGPU BIO TECH
Oral phenobarbital freeze-dried powder preparation and preparation method thereof
InactiveCN105147625AAccurate doseImprove medication complianceOrganic active ingredientsPowder deliveryDiseaseFreeze-drying
The invention relates to oral phenobarbital freeze-dried powder and a preparation method thereof. The oral phenobarbital freeze-dried powder comprises phenobarbital and a freeze-dried skeleton agent. The oral phenobarbital freeze-dried powder prepared by adopting a freeze drying technology is quick in the solution rate and accurate in the dosage, and can be used for treating diseases like neonatal jaundice.
Owner:HEFEI HUAFANG PHARMA SCI & TECH
Phenobarbital orally disintegrating tablets and preparation method thereof
InactiveCN105147632AEasy to carryImprove medication complianceOrganic active ingredientsDigestive systemAdhesiveMedicine
The invention discloses phenobarbital orally disintegrating tablets and a preparation method thereof, and belongs to the field of preparation of phenobarbital orally disintegrating tablets. The invention firstly discloses phenobarbital orally disintegrating tablets which comprise the following components in parts by weight: 1-30 parts of phenobarbital, 60-95 parts of a framework material, 1-10 parts of an adhesive, 0.1-5 parts of a corrigent and a pH regulator. The phenobarbital orally disintegrating tablets provided by the invention are good in appearance, low in the friability, good in taste, short in melting time, quick in effect, convenient to carry and good in medication compliance.
Owner:HEFEI HUAFANG PHARMA SCI & TECH
Medicinal composition for relieving fever and easing pain
The invention discloses a medicinal composition for relieving fever and easing pain. The medicinal composition is characterized by being composed of aminopyrine, phenacetin, caffeine, phenobarbital and medicinal auxiliary materials. The aminopyrine and the phenacetin are capable of inhibiting synthesis and release of thalamus opticus prostaglandin and recovering orthocrasia of heat-regulating center receptive neuron and play a role of fever relieving; meanwhile a function of pain easing is also achieved by inhibiting synthesis of prostaglandin and the like; the aminopyrine is capable of inhibiting synthesis and release of aminopyrine in partial inflammation tissue, stabilizing lysosomal enzyme and influencing phagocytosis of phagocyte and plays a role of antiinflammatory action; the caffeine is a central nervous stimulant which is capable of stimulating cerebral cortex and improving the irritability to the external world and has the effects of shrinking brain blood vessels and enhancing the effects of the two former medicines in relieving headache; the phenobarbital has functions of calming, hypnosis and anticonvulsion, the calming functions of aminopyrine and phenacetin are enhanced, and convulsions caused by fever can be also prevented.
Owner:KAMP PHARMA
Drug for curing dermatophytosis and preparation method thereof
The invention discloses a drug for curing the dermatophytosis. The drug for curing the dermatophytosis uses analgin, aminopyrine, phenacetin, caffeine, Phenobarbital and auxiliary materials. The drug for curing the dermatophytosis can effectively reduce the generation of foot fungus, eliminates the fungal infection, relieves pain and itching, eliminates the foot odor, and is fast in effect, high in cure rate, hard for repeated attack and free of side effects.
Owner:重庆市潼南区中药研究院有限公司
Medicine composition containing iodized lecithin and preparation method thereof
The invention discloses a medicine composition containing iodized lecithin and a preparation method thereof. The medicine composition containing iodized lecithin mainly comprises the following components: iodized lecithin, kaempferol, diosmin, stachydrine, blueberry anthocyanins, luteolin, chitin, puncturevine caltrop fruit saponins, phenobarbital, alpha-linolenic acid, taurine, riboflavin, nicotinic acid, amino acid, a filling agent, an adhesive, a disintegrating agent and a lubricating agent. The medicine composition has the beneficial effects that various effective components are combined through reasonable proportioning; the medicine composition achieves the functions of improving eyesight, eliminating ocular inflammation, increasing retina metabolism and regulating autoimmunity by improving ocular blood circulation, increasing corneal nutrition, resisting inflammation and oxidation and regulating the liver and kidneys, and has good prevention and treatment effects on cataract.
Owner:钟志敏
Phenobarbital sustained-release preparation and preparation method thereof
PendingCN111544405ASlow release rateLong-lasting releaseOrganic active ingredientsNervous disorderPhenobarbitalSustained-Release Preparations
The invention belongs to the field of medicinal materials and carriers, and particularly discloses a phenobarbital sustained-release preparation which comprises a phenobarbital pharmaceutical active component, an excipient and a lubricant. The phenobarbital pharmaceutical active component accounts for 25-60% of the weight of the sustained-release preparation. The excipient is prepared from a gel skeleton material, a swelling material and a diluent, the gel skeleton material accounts for 10-50% of the weight of the sustained-release preparation, the swelling material accounts for 10-30% of theweight of the sustained-release preparation, and the diluent accounts for 0-15% of the weight of the sustained-release preparation. The gel skeleton material is composed of alginate and calcium salt,and the weight ratio of alginate to calcium salt is 2: 1 to 8: 1. The lubricant accounts for 0.7-2.5% of the weight of the sustained-release preparation. After the sustained release preparation disclosed by the invention is used, acid-insoluble gel with good strength is rapidly formed, so that the phenobarbital drug release speed is reduced, the drug can be released and absorbed for a longer time,and the bioavailability of the drug is improved.
Owner:北京清析技术研究院
Phenobarbital derivatives useful in immunoassay
Phenobarbital derivatives synthesized out of the alkyl chain at the 5-position, particularly with hydrophilic properties, and carrying an active ester at the end, allow formation of aminodextran conjugates that give curves in the desired range of the assay in the ONLINE TDM microparticle assay format when matched against the Roche FPIA antibody specific for phenobarbital (''an antibody specific for phenobarbital'').
Owner:F HOFFMANN LA ROCHE & CO AG
A method, kit and application for measuring phenobarbital in blood
ActiveCN111239282BReduce the impact of the assayDisperse fastComponent separationMass Spectrometry-Mass SpectrometryPharmaceutical drug
Owner:NINGBO MUNICIPAL CENT FOR DISEASE CONTROL & PREVENTION
Extract of vicia faba beans
InactiveUS20200101125A1Nervous disorderHydroxy compound active ingredientsBiotechnologyIntraperitoneal route
The extract of Vicia faba beans is prepared by soaking beans in distilled water overnight and then boiling in a water bath to reduce the volume of aqueous extract, which is then homogenized and filtered. The filtrate is concentrated to a smaller volume, lyophilized, and powdered. The lyophilized powder is extracted with hexane to remove oils and lipids. The oil-free lyophilized powder is dissolved in ethanol solvent and extracted for eight hours under reflux, and filtered. The volume of ethanol is reduced by a rotary evaporator, and a first off-white precipitate (sample A-1) is collected, washed with ethanol, and dried at 80° C. Mass spectrometry shows a molecular weight of 200.16447 g mol−1, and an empirical formula of C9H16N2O3 is assigned. Intraperitoneal injection of mice with 50 mg / kg of A-1 twenty minutes prior to injection with strychnine protected the mice from strychnine-induced convulsions to the same extent as phenobarbitone (phenobarbital).
Owner:KING SAUD UNIVERSITY
Method for detecting residual tranquilizer medicines in meat product
The invention discloses a method for detecting residual in a plurality of tranquilizers in a meat product. The method comprises the following steps: extracting and purifying by adopting a C18 solid phase extracting column, and then detecting by adopting a gas chromatography-mass spectrometer (GC-MS), so as to rapidly and exactly detect out the variety and the content of the residual tranquilizers , including seven tranquilizers , namely, diazepam, oxazepam, estazolam, alprazolam, triazolam, phenobarbital and promethazine, in the meat product. The method is suitable for detecting multiple tranquilizers medicine residues in complex substrate meat products such as sausage; the method has the advantages of being low in detection limit, accurate, fast, easy and convenient in operation and economic in detection cost, and can be developed and applied in detection mechanisms.
Owner:广东省中山市质量计量监督检测所
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com